

Robert I Haddad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7857282/publications.pdf>

Version: 2024-02-01

247
papers

25,188
citations

9786

73
h-index

7518

151
g-index

251
all docs

251
docs citations

251
times ranked

22178
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. <i>New England Journal of Medicine</i> , 2016, 375, 1856-1867.	27.0	3,845
2	Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer. <i>New England Journal of Medicine</i> , 2007, 357, 1705-1715.	27.0	1,537
3	Recent Advances in Head and Neck Cancer. <i>New England Journal of Medicine</i> , 2008, 359, 1143-1154.	27.0	825
4	Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. <i>Journal of Clinical Oncology</i> , 2016, 34, 3838-3845.	1.6	715
5	Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 873-898.	4.9	633
6	Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 257-264.	10.7	617
7	Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. <i>Oral Oncology</i> , 2018, 81, 45-51.	1.5	589
8	Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1542-1549.	1.6	527
9	NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 479-490.	4.9	439
10	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. <i>Nature Genetics</i> , 2018, 50, 1271-1281.	21.4	438
11	Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. <i>Annals of Oncology</i> , 2011, 22, 1071-1077.	1.2	413
12	Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2011, 12, 153-159.	10.7	371
13	Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 583-594.	10.7	358
14	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. <i>British Journal of Cancer</i> , 2018, 119, 153-159.	6.4	329
15	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1104-1115.	10.7	325
16	Characterization of HPV and host genome interactions in primary head and neck cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 15544-15549.	7.1	317
17	Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 1426-1433.	27.0	290
18	Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 450-462.	10.7	287

#	ARTICLE	IF	CITATIONS
19	Head and neck cancer. <i>Lancet, The</i> , 2021, 398, 2289-2299.	13.7	280
20	NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 761-770.	4.9	263
21	Racial Survival Disparity in Head and Neck Cancer Results from Low Prevalence of Human Papillomavirus Infection in Black Oropharyngeal Cancer Patients. <i>Cancer Prevention Research</i> , 2009, 2, 776-781.	1.5	260
22	NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1429-1440.	4.9	249
23	Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. <i>Annals of Oncology</i> , 2020, 31, 942-950.	1.2	240
24	Genomic Analysis of Metastatic Cutaneous Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 1447-1456.	7.0	235
25	Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2664-2671.	3.6	233
26	Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. <i>Oral Oncology</i> , 2003, 39, 724-727.	1.5	228
27	Head and Neck Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 596-650.	4.9	213
28	Dose to Larynx Predicts for Swallowing Complications After Intensity-Modulated Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1110-1118.	0.8	211
29	Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2020, 6, 1563.	7.1	198
30	Thyroid Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 1228-1274.	4.9	194
31	HER2 Expression in Salivary Gland Carcinomas. <i>Clinical Cancer Research</i> , 2004, 10, 944-946.	7.0	193
32	Head and Neck Cancers, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1454-1487.	4.9	192
33	Frameshift events predict anti-“PD-1/L1 response in head and neck cancer. <i>JCI Insight</i> , 2018, 3, .	5.0	190
34	A Phase II Study of Gefitinib in Patients with Advanced Thyroid Cancer. <i>Thyroid</i> , 2008, 18, 317-323.	4.5	185
35	Head and Neck Cancers, Version 1.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 847-856.	4.9	185
36	Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021, 39, 840-859.	1.6	178

#	ARTICLE	IF	CITATIONS
37	Radiation Treatment Breaks and Ulcerative Mucositis in Head and Neck Cancer. <i>Oncologist</i> , 2008, 13, 886-898.	3.7	174
38	NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 224-234.	4.9	169
39	Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Related Head and Neck Cancer: A Multicenter, Phase II Trial. <i>Clinical Cancer Research</i> , 2020, 26, 5140-5152.	7.0	163
40	Trastuzumab for the Treatment of Salivary Duct Carcinoma. <i>Oncologist</i> , 2013, 18, 294-300.	3.7	155
41	Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma. <i>Cancer Research</i> , 2013, 73, 5195-5205.	0.9	153
42	Thyroid Carcinoma, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1671-1680.	4.9	147
43	Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck. <i>Cancer</i> , 2016, 122, 3632-3640.	4.1	145
44	Head and Neck Cancers, Version 2.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 917-923.	4.9	141
45	Oral Human Papillomavirus (HPV) Infection in HPV-Positive Patients With Oropharyngeal Cancer and Their Partners. <i>Journal of Clinical Oncology</i> , 2014, 32, 2408-2415.	1.6	139
46	Marital status and head and neck cancer outcomes. <i>Cancer</i> , 2015, 121, 1273-1278.	4.1	136
47	Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. <i>Annals of Oncology</i> , 2009, 20, 921-927.	1.2	134
48	Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1660-1667.	2.5	127
49	Biomarkers of HPV in Head and Neck Squamous Cell Carcinoma. <i>Cancer Research</i> , 2012, 72, 5004-5013.	0.9	122
50	Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. <i>Clinical Cancer Research</i> , 2019, 25, 5221-5230.	7.0	115
51	An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz094.	2.9	114
52	Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. <i>Cell</i> , 2022, 185, 2918-2935.e29.	28.9	113
53	Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. <i>Cancer</i> , 2013, 119, 4268-4276.	4.1	107
54	Phase I Study of Gefitinib Plus Celecoxib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2005, 23, 6976-6981.	1.6	106

#	ARTICLE	IF	CITATIONS
55	Salivary Gland Tumors Treated With Adjuvant Intensity-Modulated Radiotherapy With or Without Concurrent Chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 308-314.	0.8	104
56	The role of oral hygiene in head and neck cancer: results from International Head and Neck Cancer Epidemiology (INHANCE) consortium. <i>Annals of Oncology</i> , 2016, 27, 1619-1625.	1.2	101
57	Tipifarnib in Head and Neck Squamous Cell Carcinoma With <i>HRAS</i> Mutations. <i>Journal of Clinical Oncology</i> , 2021, 39, 1856-1864.	1.6	100
58	Dysphagia after Sequential Chemoradiation Therapy for Advanced Head and Neck Cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 2006, 134, 916-922.	1.9	96
59	Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes. <i>Bone Marrow Transplantation</i> , 2011, 46, 884-891.	2.4	96
60	Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. <i>Annals of Oncology</i> , 2018, 29, 1130-1140.	1.2	94
61	Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer. <i>Annals of Oncology</i> , 2018, 29, 1980-1986.	1.2	94
62	Anaplastic Thyroid Carcinoma, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1140-1150.	4.9	92
63	Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2003, 97, 412-418.	4.1	90
64	Positron emission tomography with ¹⁸ F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. <i>Head and Neck</i> , 2004, 26, 890-896.	2.0	87
65	Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study. <i>Clinical Cancer Research</i> , 2018, 24, 1546-1553.	7.0	86
66	Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. <i>Cancer</i> , 2009, 115, 4514-4523.	4.1	85
67	Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck. <i>JAMA Oncology</i> , 2018, 4, 1583.	7.1	84
68	Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus-Related Oropharyngeal Carcinoma. <i>JAMA Oncology</i> , 2015, 1, 907.	7.1	82
69	Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. <i>Endocrine</i> , 2017, 56, 121-128.	2.3	82
70	Examining the Need for Neck Dissection in the Era of Chemoradiation Therapy for Advanced Head and Neck Cancer. <i>JAMA Otolaryngology</i> , 2006, 132, 526.	1.2	81
71	Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. <i>Cancer Immunology Research</i> , 2016, 4, 679-687.	3.4	81
72	Clinical Practice Guidance for Radiotherapy Planning After Induction Chemotherapy in Locoregionally Advanced Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 725-733.	0.8	80

#	ARTICLE	IF	CITATIONS
73	Targeted therapies for squamous cell carcinoma of the head and neck: Current knowledge and future directions. <i>Cancer Treatment Reviews</i> , 2014, 40, 390-404.	7.7	77
74	Overcoming resistance to EGFR inhibitor in head and neck cancer: A review of the literature. <i>Oral Oncology</i> , 2012, 48, 1085-1089.	1.5	75
75	Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. <i>Oral Oncology</i> , 2012, 48, 1281-1288.	1.5	71
76	Vandetanib for the Treatment of Medullary Thyroid Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 524-529.	7.0	71
77	Medullary Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 512-530.	4.9	70
78	Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer. <i>Cancer</i> , 2010, 116, 4761-4768.	4.1	70
79	Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. <i>Annals of Oncology</i> , 2017, 28, 2526-2532.	1.2	70
80	CheckMate 141: 1â€Year Update and Subgroup Analysis of Nivolumab as Firstâ€Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. <i>Oncologist</i> , 2018, 23, 1079-1082.	3.7	70
81	Chemoradiotherapy for Adenoid Cystic Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 153-157.	1.3	67
82	Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: Evolution of the sequential treatment approach. <i>Seminars in Oncology</i> , 2004, 31, 778-785.	2.2	66
83	Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. <i>British Journal of Cancer</i> , 2016, 115, 252-260.	6.4	66
84	A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2004, 10, 4680-4687.	7.0	65
85	Nivolumab treatment beyond RECISTâ€defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. <i>Cancer</i> , 2019, 125, 3208-3218.	4.1	64
86	Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. <i>British Journal of Cancer</i> , 2011, 104, 1896-1905.	6.4	63
87	Treatment of Oral Cavity Squamous Cell Carcinoma With Adjuvant or Definitive Intensity-Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e215-e222.	0.8	61
88	A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 134-144.	0.8	61
89	The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Womenâ€™s Cancer Center Multidisciplinary Guideline. <i>Oncologist</i> , 2017, 22, 343-350.	3.7	57
90	Î²-Tubulin-II Expression Strongly Predicts Outcome in Patients Receiving Induction Chemotherapy for Locally Advanced Squamous Carcinoma of the Head and Neck: A Companion Analysis of the TAX 324 Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 6222-6228.	1.6	55

#	ARTICLE	IF	CITATIONS
91	Phase I Study of C-TPF in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2009, 27, 4448-4453.	1.6	54
92	A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN). <i>Oral Oncology</i> , 2013, 49, 835-841.	1.5	54
93	Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study. <i>Cancer Cell</i> , 2020, 38, 769-770.	16.8	54
94	Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck. <i>Oral Oncology</i> , 2005, 41, 70-76.	1.5	53
95	Patient-reported receipt of and interest in smoking cessation interventions after a diagnosis of cancer. <i>Cancer</i> , 2011, 117, 2961-2969.	4.1	53
96	Best Practice in Systemic Therapy for Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 815.	2.8	53
97	Docetaxel, Cisplatin, 5-Fluorouracil (TPF)-Based Induction Chemotherapy for Head and Neck Cancer and the Case for Sequential, Combined-Modality Treatment. <i>Oncologist</i> , 2003, 8, 35-44.	3.7	52
98	Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. <i>Annals of Oncology</i> , 2010, 21, 342-347.	1.2	52
99	Endoscopic Management of Hypopharyngeal Stenosis after Organ Sparing Therapy for Head and Neck Cancer. <i>Laryngoscope</i> , 2004, 114, 1924-1931.	2.0	51
100	Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 2939-2949.	7.0	51
101	Management of elderly patients with locoregionally confined head and neck cancer. <i>Lancet Oncology</i> , 2017, 18, e274-e283.	10.7	51
102	<i>CDKN2A</i> Alterations and Response to Immunotherapy in Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 4025-4035.	7.0	51
103	Efficacy and Toxicity of Chemoradiotherapy Using Intensity-Modulated Radiotherapy for Unknown Primary of Head and Neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1405-1411.	0.8	50
104	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. <i>Cancer Immunology Research</i> , 2020, 8, 1075-1084.	3.4	47
105	Relationship Between Radiation Treatment Time and Overall Survival After Induction Chemotherapy for Locally Advanced Head-and-Neck Carcinoma: A Subset Analysis of TAX 324. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e813-e818.	0.8	45
106	Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2022, 28, 468-478.	7.0	45
107	Open-Label, Long-Term Safety Study of Cevimeline in the Treatment of Postirradiation Xerostomia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1369-1376.	0.8	44
108	Factors associated with smoking abstinence among smokers and recent-quitters with lung and head and neck cancer. <i>Lung Cancer</i> , 2012, 76, 144-149.	2.0	44

#	ARTICLE	IF	CITATIONS
109	Polymerase Chain Reaction Detection of HPV in Squamous Carcinoma of the Oropharynx. American Journal of Clinical Pathology, 2010, 134, 36-41.	0.7	43
110	Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncology, 2017, 67, 61-69.	1.5	42
111	Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer. Frontiers in Oncology, 2017, 7, 191.	2.8	42
112	Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck. Cancer, 2001, 91, 548-554.	4.1	41
113	Organ Preservation and Treatment Toxicity With Induction Chemotherapy Followed by Radiation Therapy or Chemoradiation for Advanced Laryngeal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 371-378.	1.3	41
114	Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial. Annals of Oncology, 2016, 27, 1585-1593.	1.2	41
115	Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology, 2017, 35, 6009-6009.	1.6	41
116	Management of treatment-related toxicities in advanced medullary thyroid cancer. Cancer Treatment Reviews, 2018, 66, 64-73.	7.7	38
117	Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. , 2022, 10, e003026.		38
118	HPV16 transmission between a couple with HPV-related head and neck cancer. Oral Oncology, 2008, 44, 812-815.	1.5	37
119	Combined antegrade and retrograde esophageal dilation for head and neck cancer-related complete esophageal stenosis. Laryngoscope, 2010, 120, 261-266.	2.0	35
120	Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study. Oral Oncology, 2015, 51, 751-758.	1.5	34
121	Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck. JAMA Oncology, 2019, 5, 1170.	7.1	34
122	EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).. Journal of Clinical Oncology, 2019, 37, 6012-6012.	1.6	34
123	A phase II study of nivolumab (N) plus ipilimumab (I) in radioiodine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC).. Journal of Clinical Oncology, 2020, 38, 6513-6513.	1.6	34
124	Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer. Oral Oncology, 2019, 95, 120-126.	1.5	33
125	Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series. Oral Diseases, 2020, 26, 325-333.	3.0	33
126	Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial. Journal of Clinical Oncology, 2020, 38, 2773-2781.	1.6	33

#	ARTICLE	IF	CITATIONS
127	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012.. Journal of Clinical Oncology, 2016, 34, 6012-6012.	1.6	33
128	Evaluating the Utility and Prevalence of HPV Biomarkers in Oral Rinses and Serology for HPV-related Oropharyngeal Cancer. Cancer Prevention Research, 2019, 12, 689-700.	1.5	32
129	A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma. Oral Oncology, 2021, 119, 105366.	1.5	31
130	Chemoradiation-Induced Cell Loss in Human Submandibular Glands. Laryngoscope, 2005, 115, 958-964.	2.0	30
131	Mouthwash use and cancer of the head and neck: a pooled analysis from the International Head and Neck Cancer Epidemiology Consortium. European Journal of Cancer Prevention, 2016, 25, 344-348.	1.3	30
132	Cabozantinib in Patients with Advanced Merkel Cell Carcinoma. Oncologist, 2018, 23, 814-821.	3.7	30
133	The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC).. Journal of Clinical Oncology, 2012, 30, 5501-5501.	1.6	30
134	Mucosal Melanoma of the Head and Neck. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 320-338.	4.9	29
135	Acupuncture for Dysphagia After Chemoradiation Therapy in Head and Neck Cancer: A Case Series Report. Integrative Cancer Therapies, 2010, 9, 284-290.	2.0	28
136	Novel biomarker panel predicts prognosis in human papillomavirus-negative oropharyngeal cancer. Cancer, 2012, 118, 1811-1817.	4.1	28
137	Human papillomavirus (HPV) 16 antibodies at diagnosis of HPV-related oropharyngeal cancer and antibody trajectories after treatment. Oral Oncology, 2017, 67, 77-82.	1.5	28
138	Multidisciplinary Approach to Cancer Treatment: Focus on Head and Neck Cancer. Dental Clinics of North America, 2008, 52, 1-17.	1.8	27
139	Induction Chemotherapy for Locoregionally Advanced Head and Neck Cancer: Past, Present, Future?. Oncologist, 2013, 18, 288-293.	3.7	27
140	Success of endoscopic pharyngoesophageal dilation after head and neck cancer treatment. Laryngoscope, 2013, 123, 3066-3073.	2.0	27
141	Barriers to clinical trial recruitment in head and neck cancer. Oral Oncology, 2015, 51, 203-211.	1.5	27
142	Rate of Pathologic Complete Responses to Docetaxel, Cisplatin, and Fluorouracil Induction Chemotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngology, 2006, 132, 678.	1.2	26
143	Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1036-1044.	0.8	26
144	The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers. Oncologist, 2020, 25, 598-608.	3.7	26

#	ARTICLE	IF	CITATIONS
145	Everolimus in Anaplastic Thyroid Cancer: A Case Series. <i>Frontiers in Oncology</i> , 2019, 9, 106.	2.8	25
146	Behavior of oral squamous cell carcinoma in subjects with prior lichen planus. <i>Otolaryngology - Head and Neck Surgery</i> , 2007, 136, 401-404.	1.9	24
147	Induction Chemotherapy in Locally Advanced Head and Neck Cancer: A New Standard of Care?. <i>Hematology/Oncology Clinics of North America</i> , 2008, 22, 1155-1163.	2.2	24
148	A Pilot Surrogate Endpoint Biomarker Study of Celecoxib in Oral Premalignant Lesions. <i>Cancer Prevention Research</i> , 2008, 1, 339-348.	1.5	24
149	Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 137-145.	0.8	24
150	Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6511-6511.	1.6	24
151	Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. <i>Cancer Biomarkers</i> , 2017, 19, 129-136.	1.7	22
152	Swallowing Function following Postchemoradiotherapy Neck Dissection. <i>Otolaryngology - Head and Neck Surgery</i> , 2011, 145, 428-434.	1.9	21
153	Acupuncture for dysphagia after chemoradiation in head and neck cancer: Rationale and design of a randomized, sham-controlled trial. <i>Contemporary Clinical Trials</i> , 2012, 33, 700-711.	1.8	21
154	Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma. <i>Oral Oncology</i> , 2020, 106, 104690.	1.5	21
155	Improved outcomes in PI3K-pathway-altered metastatic HPV oropharyngeal cancer. <i>JCI Insight</i> , 2018, 3, .	5.0	21
156	Erythropoietin to treat anaemia in patients with head and neck cancer. <i>Lancet, The</i> , 2004, 363, 79-80.	13.7	20
157	Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy. <i>BMC Cancer</i> , 2014, 14, 473.	2.6	20
158	Patterns of failure after reirradiation with intensity-modulated radiation therapy and the competing risk of out-of-field recurrences. <i>Oral Oncology</i> , 2016, 61, 19-26.	1.5	20
159	Nivolumab (Nivo) vs investigator's choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6019-6019.	1.6	20
160	Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. <i>Seminars in Oncology</i> , 2003, 30, 84-88.	2.2	19
161	Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy. <i>Annals of Oncology</i> , 2012, 23, 2391-2398.	1.2	19
162	Human papillomavirus-associated adenocarcinoma of the base of the tongue. <i>Human Pathology</i> , 2013, 44, 1516-1523.	2.0	19

#	ARTICLE	IF	CITATIONS
163	Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2018, 82, 83-90.	1.5	19
164	Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma. <i>European Journal of Cancer</i> , 2019, 113, 1-9.	2.8	19
165	Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 6008-6008.	1.6	19
166	KEYNOTE-689: Phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS6090-TPS6090.	1.6	19
167	Acupuncture for Chemoradiation Therapy-Related Dysphagia in Head and Neck Cancer: A Pilot Randomized Sham-Controlled Trial. <i>Oncologist</i> , 2016, 21, 1522-1529.	3.7	18
168	Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. <i>Oncologist</i> , 2022, 27, e194-e198.	3.7	18
169	Organ Preservation for Adenoid Cystic Carcinoma of the Larynx. <i>Oncologist</i> , 2013, 18, 579-583.	3.7	17
170	Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients. , 2016, 4, 32.		17
171	Weekly paclitaxel, carboplatin, cetuximab, and docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2019, 30, 471-477.	1.2	17
172	Utilizing computed tomography as a road map for designing selective and superselective neck dissection after chemoradiotherapy. <i>Otolaryngology - Head and Neck Surgery</i> , 2010, 143, 367-374.	1.9	16
173	Human Papillomavirus-Associated Oropharynx Cancer (HPV-OPC): Treatment Options. <i>Current Treatment Options in Oncology</i> , 2014, 15, 595-610.	3.0	16
174	Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States. <i>Journal of Medical Economics</i> , 2020, 23, 442-447.	2.1	16
175	Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2020, 105, 104676.	1.5	16
176	Integration of chemotherapy in the curative treatment of locally advanced head and neck cancer. <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 331-338.	2.4	15
177	Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2018, 85, 29-34.	1.5	15
178	Seeking alternative biological therapies: The future of targeted molecular treatment. <i>Oral Oncology</i> , 2009, 45, 447-453.	1.5	14
179	JAVELIN head and neck 100: A phase 3 trial of avelumab in combination with chemoradiotherapy (CRT) vs CRT for 1st-line treatment of locally advanced squamous cell carcinoma of the head and neck (LA) Tj ETQq1 1 0.784314 rgBT1/Overlo		
180	Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders. , 2022, 10, e004034.		14

#	ARTICLE	IF	CITATIONS
181	Long Term Survival With Adjuvant Carboplatin, Paclitaxel, and Radiation Therapy in Anaplastic Thyroid Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 104.	1.3	13
182	Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma. <i>European Journal of Cancer</i> , 2019, 123, 138-145.	2.8	13
183	How to Incorporate New Tyrosine Kinase Inhibitors in the Treatment of Patients With Medullary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3618-3620.	1.6	12
184	Exposed bone in patients with head and neck cancer treated with radiation therapy: An analysis of the Observational Study of Dental Outcomes in Head and Neck Cancer Patients (OraRad). <i>Cancer</i> , 2022, 128, 487-496.	4.1	12
185	Retropharyngeal Nodes in Hypopharynx Cancer on Positron Emission Tomography. <i>Journal of Clinical Oncology</i> , 2007, 25, 599-601.	1.6	11
186	Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6011-6011.	1.6	11
187	Palliative chemotherapy in patients with salivary gland neoplasms and preliminary reports of 2 recent phase II studies with trastuzumab and gemcitabine. <i>Clinical Advances in Hematology and Oncology</i> , 2003, 1, 226-8.	0.3	11
188	Emerging drugs for head and neck cancer. <i>Expert Opinion on Emerging Drugs</i> , 2006, 11, 461-467.	2.4	10
189	Metastatic Human Papillomavirus-Positive Nasopharyngeal Carcinoma With an Unusual Pattern of Aggressive Hematogenous Spread. <i>Journal of Clinical Oncology</i> , 2012, 30, e321-e323.	1.6	10
190	Larynx Preservation: A Debate Worth Preserving. <i>Journal of Clinical Oncology</i> , 2013, 31, 3170-3170.	1.6	10
191	New Developments in Thyroid Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 705-707.	4.9	10
192	Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study. <i>Lung Cancer</i> , 2021, 160, 78-83.	2.0	10
193	Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia. <i>Cancer Research Communications</i> , 2021, 1, 30-40.	1.7	10
194	Novel agents for the treatment of mucositis. <i>The Journal of Supportive Oncology</i> , 2007, 5, 33-9.	2.3	10
195	Optimizing Tobacco Cessation Resource Awareness Among Patients and Providers. <i>Journal of Oncology Practice</i> , 2016, 12, e77-e82.	2.5	9
196	Population-based validation of the recursive partitioning analysis-based staging system for oropharyngeal cancer. <i>Head and Neck</i> , 2016, 38, 1530-1538.	2.0	9
197	Locally Advanced Head and Neck Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 237-244.	3.8	9
198	Induction Chemotherapy in Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, e52-e53.	1.6	8

#	ARTICLE	IF	CITATIONS
199	Ensuring Head and Neck Oncology Patients Receive Recommended Pretreatment Dental Evaluations. <i>Journal of Oncology Practice</i> , 2015, 11, 151-154.	2.5	8
200	Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors. <i>Oral Oncology</i> , 2018, 81, 1-9.	1.5	8
201	A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 132-139.	0.8	8
202	IMRT-based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparing. <i>Head and Neck</i> , 2019, 41, 959-966.	2.0	8
203	Keynote 48: Is it really for everyone?. <i>Oral Oncology</i> , 2020, 105, 104762.	1.5	8
204	Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19. <i>Oral Oncology</i> , 2021, 112, 105087.	1.5	8
205	Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience. <i>Head and Neck</i> , 2016, 38, E1618-24.	2.0	7
206	Patient-oriented toxicity endpoints after head and neck reirradiation with intensity modulated radiation therapy. <i>Oral Oncology</i> , 2017, 73, 160-165.	1.5	7
207	Circulating tumor cell analysis in locally advanced and metastatic squamous cell carcinoma of the head and neck. <i>Laryngoscope Investigative Otolaryngology</i> , 2020, 5, 1063-1069.	1.5	7
208	Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6053-6053.	1.6	7
209	Biomarker analysis in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M) Tj ETQq1 1 0.784314 rgBT /Overlock (LUX-H&N1).. <i>Journal of Clinical Oncology</i> , 2015, 33, 6023-6023.	1.6	7
210	Randomized phase II trial of cixutumumab (CIX) alone or with cetuximab (CET) for refractory recurrent/metastatic squamous cancer of head and neck (R/M-SCCHN).. <i>Journal of Clinical Oncology</i> , 2013, 31, 6030-6030.	1.6	6
211	A randomized phase II study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6082-6082.	1.6	6
212	Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes. <i>Head and Neck</i> , 2022, 44, 722-734.	2.0	6
213	Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 303-306.	2.3	5
214	Progress and perspectives in chemoprevention of head and neck cancer. <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 339-355.	2.4	5
215	Integrating novel agents into the curative treatment of head and neck cancer. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 157-159.	2.4	5
216	Title is missing!., 2017, , .		4

#	ARTICLE	IF	CITATIONS
217	Re: Randomized Trial of Induction Chemotherapy With Cisplatin and 5-Fluorouracil With or Without Docetaxel for Larynx Preservation. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1157-1158.	6.3	3
218	Antiangiogenic agents in head and neck squamous cell carcinoma: Tired of going solo. <i>Cancer</i> , 2016, 122, 3592-3595.	4.1	3
219	Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. <i>Oral Oncology</i> , 2019, 97, 82-91.	1.5	3
220	Patient reported outcomes in patients with head and neck cancer treated with concurrent chemoradiation with weekly versus bolus cisplatin. <i>Head and Neck</i> , 2020, 42, 3670-3677.	2.0	3
221	The AIM-HN Study: A pivotal study evaluating the efficacy of tipifarnib in patients with recurrent or metastatic head and neck squamous cell carcinoma with <i>HRAS</i> mutations.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS6087-TPS6087.	1.6	3
222	Association between radiation dose to organs at risk and acute patient reported outcome during radiation treatment for head and neck cancers. <i>Head and Neck</i> , 2022, , .	2.0	3
223	Use of Fluoro- ¹⁸ F-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2022, 148, 268.	2.2	3
224	Medullary thyroid cancer: advances in treatment and management of common adverse events associated with therapy. <i>Community Oncology</i> , 2012, 9, 188-197.	0.2	2
225	Sequential and Concurrent Chemoradiation. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 1061-1074.	2.2	2
226	Locally Advanced Head and Neck Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, 237-244.	3.8	2
227	The Evolution of Induction Chemotherapy in Locally Advanced Squamous Cell Cancer of the Head and Neck. , 2005, , 171-185.		2
228	Clinical Decision-making About Neoadjuvant Nivolumab Plus Ipilimumabâ€”Reply. <i>JAMA Oncology</i> , 2021, 7, 309.	7.1	1
229	Multidisciplinary Approach of Unresectable Head and Neck Cancer. , 2016, , 617-624.		1
230	Interim results from a phase II study of CC-486 in previously treated patients (pts) with locally advanced/metastatic nasopharyngeal cancer (NPC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6029-6029.	1.6	1
231	Analysis of immune infiltrates in a genomically characterized clinical cohort of head and neck squamous cell carcinoma (HNSCC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6052-6052.	1.6	1
232	Characterization of potential predictive biomarkers of response to nivolumab in CheckMate-141 in patients with squamous cell carcinoma of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5-5.	1.6	1
233	The AIM-HN and SEQ-HN study: A pivotal study evaluating the efficacy of tipifarnib in patients with head and neck squamous cell carcinoma (HNSCC) with <i>hras</i> mutations (AIM-HN) and the impact of <i>hras</i> mutations on response to first line systemic therapies for HNSCC (SEQ-HN).. <i>Journal of Clinical Oncology</i> . 2020. 38. TPS6593-TPS6593.	1.6	1
234	Head and neck cancer: high-end technology is no guarantee of high-quality care â€” Authors' reply. <i>Lancet</i> , The, 2022, 399, 2102.	13.7	1

#	ARTICLE	IF	CITATIONS
235	Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2003, 97, 1589-1589.	4.1	0
236	Human papillomavirus-associated adenocarcinoma of the palatine tonsil reply. <i>Human Pathology</i> , 2014, 45, 895.	2.0	0
237	Toward a Personalized Approach in the Treatment of Salivary Ductal Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1269-1270.	4.9	0
238	Reply to "Keynote 48: Is it really for everyone?". <i>Oral Oncology</i> , 2021, 115, 105108.	1.5	0
239	Genetic ancestry and clinical outcomes to immune checkpoint inhibitors among seven common cancers.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10536-10536.	1.6	0
240	Multidisciplinary Approach of Unresectable Head and Neck Cancer. , 2011, , 333-337.		0
241	Differences between gene mutation profile and outcome of Merkel cell polyomavirus (MCPyV) positive and negative Merkel cell carcinoma (MCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9577-9577.	1.6	0
242	Impact of dental insurance coverage on presentation, long-term outcomes, and symptom burden in locally advanced head and neck cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18230-e18230.	1.6	0
243	Targeted therapy: Precision comes to life. , 2020, , 39-51.		0
244	Optimizing Treatment for Head and Neck Cancers: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 982-984.	4.9	0
245	Advances in Collaborative Practice for Patients With Head and Neck Cancers. <i>Journal of the Advanced Practitioner in Oncology</i> , 2017, 8, 261-265.	0.4	0
246	A 49-year-old male with locally advanced squamous cell carcinoma of the head and neck: the case for sequential chemoradiotherapy. <i>Clinical Advances in Hematology and Oncology</i> , 2003, 1, 58-60; discussion 61-2.	0.3	0
247	Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2622-2622.	1.6	0